TCGX Leads $250 Million PIPE Financing for Zai Lab

TCGX led a $250 million PIPE financing for Zai Lab Limited, involving the sale of 11,340,000 American Depositary Shares at $22.04 each. The net proceeds will primarily support the global development of Zai Lab's DLL3-targeting antibody-drug conjugate, zocilurtatug pelitecan. The transaction is expected to close on or about October 27, 2026, pending customary closing conditions.